Join        Login             Stock Quote

Auxilium (AUXL) Says FDA Accepts sBLA For XIAFLEX

 December 27, 2012 07:22 AM

(By Balachander) Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL) said the U.S. health regulators have accepted for filing and granted standard review status to its supplemental Biologics License Application (sBLA) for XIAFLEX for the potential treatment of Peyronie's disease (PD).

The Malvern, Pennsylvania-based company expects the U.S. Food and Drug Administration (FDA) to take action on the application by September 6, 2013.

XIAFLEX is currently approved in the U.S., EU, Canada and Switzerland to treat adult Dupuytren's contracture patients with a palpable cord.  XIAFLEX for the treatment of PD was granted orphan designation in the U.S. by the FDA in January 1996 and, if approved by the FDA, is expected to be the first and only biologic therapy indicated for the treatment of PD.

[Related -Three Stocks Set For FDA News In Early December]

PD is the development of collagen plaque, or scar tissue, on the shaft of the penis that may harden and reduce flexibility, causing the penis to deform in a bend or arc during erection.

In a two identical late-stage double-blind placebo-controlled IMPRESS studies, the company said ,XIAFLEX demonstrated statistically significant improvement in the co-primary endpoints of penile curvature deformity and patient-reported bother versus placebo. Serious adverse events included corporal rupture (penile fracture) in 3 subjects in the placebo controlled studies.

The stock, which has been trading in the 52-week range of $16.98 to $29.37, ended at $18.33 on Wednesday.

iOnTheMarket Premium


Post Comment -- Login is required to post message
Alert for new comments:
Your email:
Your Website:

rss feed

Latest Stories

article imageThe S&P 500’s Worrisome Downturn In Drawdown

Last Friday I reviewed some of the bearish signals that were casting dark shadows across the US stock read on...

article imageADP: Private-Sector Employment Rises A Solid 200k In September

The pace of growth for private-sector employment picked up in September, according to this morning’s ADP read on...

article imageTreasury Market’s Inflation Expectations Tumble

The odds for a Fed rate hike are falling like a stone, or so it appears based on the implied inflation read on...

article imageEmerging Market Stocks: Last Week’s Red-Ink Leader

Value investors on the lookout for bargains have recently been eyeing up the battered corner of emerging read on...

Popular Articles

Daily Sector Scan
Partner Center

Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.